Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).
Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida.
Moderator: Robert Rifkin, MD
Participants: Corey Cutler, MD; Pere Gascon, MD, PhD; Mark McCamish, MD, PhD
This program is supported by Sandoz Inc.
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).
David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.
Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1). To see the French language version of this newsreel, please click here.
Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
